Amyloidosis
Drug research and approvals for amyloidosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 229 studies of amyloidosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 21 drug trials for it since 2013, FDA has 8 approved and 20 open orphan designations naming it, and the EU has 8 authorised medicines for it.
- Recruiting worldwide: 229
- Trials authorized in Canada: 21
- FDA orphan approvals: 8
- EU medicines: 8
- CMN LIFU for Enhanced Amyloid Reduction (CLEAR Study)NCT07866768 · Not applicable · University of California, San Francisco · starts Nov 1, 2026
- Exploratory Study of Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Patients With Mild Alzheimer's Disease…NCT07863011 · Not applicable · ReadyCure Inc. · starts Oct 26, 2026
- Restoring Cervical Lymphatic Drainage in Alzheimer's DiseaseNCT07854327 · Not applicable · University of Siena · starts Jul 1, 2026
- SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell DisordersNCT07850284 · Not reported · Mayo Clinic · starts Aug 25, 2026
- A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)NCT07843459 · Phase 1 · Eli Lilly and Company · starts Oct 7, 2026
- Clinical Evaluation of a Toothpaste for Dental Plaque Reduction and Prevention of Gum ProblemsNCT07842991 · Phase 3 · Colgate Palmolive · starts Jul 20, 2026
- Beta-amyloid PET/CT to Measure Potential Therapeutic Response in AL-CANCT07829705 · Phase 2 · Peking Union Medical College Hospital · starts Jun 3, 2020
- PCCT-Defined High-Risk Plaque and Future Coronary Events: The PREDICT StudyNCT07822737 · Not reported · Beijing Chao Yang Hospital · starts Jan 18, 2025
- Study of Acoramidis in Patients With Transthyretin Amyloid CardiomyopathyNCT07791160 · Not reported · Bayer · starts Sep 7, 2026
Approved 3
- InotersenTransthyretin mRNA antisense inhibitor
- AcoramidisTransthyretin stabiliser
- TafamidisTransthyretin stabiliser
Phase 3 6
- DexamethasoneGlucocorticoid receptor agonist
- Bortezomib26S proteasome inhibitor
- DaratumumabLymphocyte differentiation antigen CD38 inhibitor
- CyclophosphamideDNA inhibitor
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- PatisiranTransthyretin mRNA RNAi inhibitor
Phase 2 9
- MiridesapSerum amyloid P-component cross-linking agent
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- IdelalisibPI3-kinase p110-delta subunit inhibitor
- PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- IbrutinibTyrosine-protein kinase BTK inhibitor
- VenetoclaxApoptosis regulator Bcl-2 inhibitor
- BirtamimabLight chain aggregates inhibitor
- DezamizumabSerum amyloid P-component inhibitor
- Iodine I124 evuzamitide
Phase 1 or earlier 10
- GSK-294
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- Belantamab mafodotinTumor necrosis factor receptor superfamily member 17 binding agent
- Carfilzomib26S proteasome inhibitor
- APG-2575Apoptosis regulator Bcl-2 inhibitor
- Anselamimab
- Eplontersen sodiumTransthyretin mRNA antisense inhibitor
- Nexiguran
- Ziclumeran
- SelinexorExportin-1 inhibitor
How its trials ended
562 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 118 whose ending is known, 47% met their primary endpoint, 4% missed it and 49% stopped early.
- Ongoing22240%
- Completed, result not reported16730%
- Met its primary endpoint5510%
- Status unknown5510%
- Stopped: other or unclear326%
- Stopped: enrollment or feasibility122%
- Stopped: sponsor or business decision61%
- Missed its primary endpoint51%
- Stopped: lack of efficacy41%
- Stopped: safety41%
| Oct 29, 2026 | A phase 3 multicenter, randomized, open-label study evaluating the safety and efficacy of etentamig (ABBV-383) compared to daratumumab, cyclophosphamide,…Etentamig (ABBV-383) | AbbVie | Pending |
| Feb 26, 2026 | A phase 1/2 study of linvoseltamab in patients with relapsed or refractory systemic light chain amyloidosis (LINKER-AL2)Linvoseltamab (REGN5458) | Regeneron | Pending |
| Oct 31, 2025 | A phase 1b/2 study of AZD0120 (also known as GC012F), a chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 and B-cell maturation antigen (BCMA) in…AZD0120 (GC012F) | AstraZeneca Pharmaceuticals | Ongoing |
| Oct 29, 2025 | Triton-pn: a phase 3, global, randomized, open-label study to evaluate the efficacy and safety of nucresiran in patients with hereditary transthyretin-mediated…Nucresiran (ALN-TTRSC04) / Vutrisiran (ALN-TTRSC02) | Alnylam Pharmaceuticals | Ongoing |
| Jun 20, 2025 | A phase 3 global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of nucresiran in patients with transthyretinmediated…Nucresiran (ALN-TTRSC04) | Alnylam Pharmaceuticals | Ongoing |
| Oct 21, 2024 | A phase 3, randomized, multicenter, double-blind, placebo controlled study of acoramidis for transthyretin amyloidosis prevention in the young (act-early trial)Acoramidis | Eidos Therapeutics | Ongoing |
| Feb 1, 2024 | A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of intrathecally…Mivelsiran (aln-app) | Alnylam Pharmaceuticals | Ongoing |
| Jan 6, 2022 | A phase 3, open-label, multicenter, single-arm study to evaluate the efficacy and safety of acoramidis in subjects with symptomatic transthyretin amyloid…Acoramidis (AG10) | Eidos Therapeutics | Pending |
| Jan 6, 2022 | A phase 2, multicohort study of daratumumab-based therapies in participants with amyloid light chain (AL) amyloidosisDaratumumab (JNJ-54767414) | Johnson & Johnson | Ongoing |
| May 12, 2021 | A phase 3, randomized, multicenter, double-blind, placebo-controlled, efficacy and safety study of birtamimab plus standard of care vs. placebo plus standard…Birtamimab | Prothena Therapeutics Limited | Ongoing |
| Mar 20, 2025 | AmvuttraTreatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular… | Alnylam Pharmaceuticals, Inc. | Approved |
| Nov 22, 2024 | AttrubyTreatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular… | BridgeBio Pharma, Inc. | Approved |
| Dec 21, 2023 | WainuaTreatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults | Ionis Pharmaceuticals, Inc. | Approved |
| Jun 13, 2022 | AmvuttraTreatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults | Alnylam Pharmaceuticals, Inc. | Approved |
| Jan 15, 2021 | Darzalex FasproIn combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adult patients with newly diagnosed light chain… | Janssen Research & Development, LLC | Approved |
| May 3, 2019 | Vyndaqel; VyndamaxVYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis… | FoldRx Pharmaceuticals, Inc., a subsidiary of Pfizer Inc. | Approved |
| Oct 5, 2018 | Tegsedi™TEGSEDI® is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. | Akcea Therapeutics, Inc. | Approved |
| Aug 10, 2018 | OnpattroONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. | Alnylam Pharmaceuticals, Inc. | Approved |
| Jun 1, 2026 | Zamubafusp alfaTreatment of light chain (AL)-associated amyloidosis | Attralus, Inc. | Designated |
| Dec 2, 2025 | Revlucabtagene autoleucelTreatment of amyloid light chain amyloidosis | Nexcella, Inc. | Designated |
| Jul 3, 2025 | DiflunisalTreatment of transthyretin-mediated amyloidosis | Purpose Pharma International AB | Designated |
| Jun 5, 2025 | Small interfering ribonucleic acid -GalNAc conjugate…Treatment of transthyretin amyloidosis (ATTR amyloidosis) | Chengdu Brilliant Pharmaceutical Co., Ltd. | Designated |
| Mar 14, 2025 | CRISPR-associated protein 9-based TTR gene editing therapyTreatment of transthyretin-mediated amyloidosis-ATTR | Accuredit Therapeutics US Ltd. | Designated |
| Feb 4, 2025 | RNA interference (RNAi) therapeutic, that targets the…Treatment of transthyretin (TTR) -mediated amyloidosis (ATTR amyloidosis) | Alnylam Pharmaceuticals, Inc. | Designated |
| Oct 30, 2024 | A fusion protein of humanized immunoglobulin G1 (IgG1) with…Treatment of transthyretin-associated (ATTR) amyloidosis | Attralus, Inc. | Designated |
| Sep 18, 2026 | Tafamidis AccordTafamidis · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Jul 17, 2025 | AttrogyDiflunisal | Purpose Pharma International AB | EMA ↗ |
| Mar 6, 2025 | WainzuaEplontersen | AstraZeneca AB | EMA ↗ |
| Feb 10, 2025 | BeyonttraAcoramidis | Bayer AG | EMA ↗ |
| Sep 15, 2022 | AmvuttraVutrisiran · orphan | Alnylam Netherlands B.V. | EMA ↗ |
| Aug 27, 2018 | OnpattroPatisiran · orphan | Alnylam Netherlands B.V. | EMA ↗ |
| Jul 6, 2018 | TegsediInotersen · orphan | Akcea Therapeutics Ireland Limited | EMA ↗ |
| Nov 16, 2011 | VyndaqelTafamidis · orphan | Pfizer Europe MA EEIG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA